CDMO for Cell and Gene Therapy
Nowadays we are seeing an unprecedented progress in the number of new cell and gene therapy drug candidates.
The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is expected to grow at an impressive double-digit rate of 33.82% and reach a value of $25,002.1 million in 2027.
However, in cell and gene therapy development, moving a drug from a biological concept to a manufacturable treatment can be a tremendous challenge.
Sofpromed facilitates expert CDMO services for cell and gene therapy developers worldwide, particularly in the context of early phase clinical trials.
These services include cell line development, cell banking, process development, technology transfer, scale up, and GMP manufacturing in the United States and Europe.